MENU
+Compare
SBIO
ETF ticker: NYSE ARCA
AS OF
Sep 5 closing price
Price
$37.01
Change
+$0.86 (+2.38%)
Net Assets
84.11M

SBIO stock forecast, quote, news & analysis

The investment seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the S-Network® Medical Breakthroughs Index... Show more

Category: #Health
SBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
These past five trading days, the ETF lost 0.00% with an average daily volume of 0 shares traded.The ETF tracked a drawdown of 0% for this period.
Interact to see
Advertisement
A.I.Advisor
a Summary for SBIO with price predictions
Sep 05, 2025

SBIO's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for SBIO turned positive on August 13, 2025. Looking at past instances where SBIO's MACD turned positive, the stock continued to rise in of 55 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 02, 2025. You may want to consider a long position or call options on SBIO as a result. In of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The 50-day moving average for SBIO moved above the 200-day moving average on August 14, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SBIO advanced for three days, in of 315 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 206 cases where SBIO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SBIO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

SBIO broke above its upper Bollinger Band on September 05, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are BioCryst Pharmaceuticals (NASDAQ:BCRX), Novavax (NASDAQ:NVAX).

Industry description

The investment seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the S-Network® Medical Breakthroughs Index. The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.

Market Cap

The average market capitalization across the ALPS Medical Breakthroughs ETF ETF is 1.83B. The market cap for tickers in the group ranges from 89.86M to 9.2B. VRNA holds the highest valuation in this group at 9.2B. The lowest valued company is STRO at 89.86M.

High and low price notable news

The average weekly price growth across all stocks in the ALPS Medical Breakthroughs ETF ETF was 6%. For the same ETF, the average monthly price growth was 11%, and the average quarterly price growth was 21%. MLYS experienced the highest price growth at 125%, while MBX experienced the biggest fall at -23%.

Volume

The average weekly volume growth across all stocks in the ALPS Medical Breakthroughs ETF ETF was 65%. For the same stocks of the ETF, the average monthly volume growth was -4% and the average quarterly volume growth was 61%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 58
P/E Growth Rating: 79
Price Growth Rating: 52
SMR Rating: 91
Profit Risk Rating: 86
Seasonality Score: -25 (-100 ... +100)
View a ticker or compare two or three
SBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
ALPS ETFPO Box 328Denver
Phone
855.724.0450
Web
www.alpsfunds.com